← back to search

Todd Riehl

Gene Therapy Laboratory · FR
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, and Cancer Genomics and Diagnostics.
h-index
20
citations
5,509
works
50
NIH funding
primary concept
email

Recent publications

Pre‐ and post‐treatment blood‐based genomic landscape of patients with <i>ROS1</i> or <i>NTRK</i> fusion‐positive solid tumours treated with entrectinib
Molecular Oncology 2022cited by 20position: middledoi
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers
Cancer Discovery 2020cited by 123position: middledoi
1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib
Annals of Oncology 2020cited by 4position: middledoi
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
The Lancet Oncology 2019cited by 1,726position: middledoi
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
The Lancet Oncology 2019cited by 531position: middledoi
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
Journal of Clinical Oncology 2018cited by 326position: middledoi
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
British Journal of Haematology 2018cited by 22position: middledoi
Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
JAMA Oncology 2017cited by 401position: middledoi
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
The Lancet Oncology 2016cited by 383position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

José Baselga · Vall d'Hebron Institute of Oncology3 papers (2017–2020)Ian Chau · Royal Marsden NHS Foundation Trust3 papers (2017–2020)Jean‐Yves Blay · International Network for Economic, Social and Cultural Rights3 papers (2017–2020)Vivek Subbiah · International Drug Development3 papers (2017–2020)Igor Puzanov · Roswell Park Comprehensive Cancer Center3 papers (2017–2020)Noopur Raje · Harvard University3 papers (2017–2020)A. Craig Lockhart · Medical University of South Carolina3 papers (2017–2020)David M. Hyman · Mayo Clinic in Florida3 papers (2017–2020)Bethany Pitcher · Princess Margaret Cancer Centre3 papers (2017–2020) · 2 papers (2020–2022)Timothy R. Wilson · National Institute of Allergy and Infectious Diseases2 papers (2020–2022)Rafał Dziadziuszko · Université Grenoble Alpes2 papers (2020–2022)Martina Makrutzki · Roche (Switzerland)2 papers (2017–2018)Eric J. Sherman · CancerCare2 papers (2016–2020)Brian Simmons · Dartmouth Psychiatric Research Center2 papers (2018–2022)Eli L. Diamond · Histiocyte Society2 papers (2017–2020)Jürgen Wolf · Université Grenoble Alpes2 papers (2017–2018)Bruno C. Medeiros · Stanford Medicine1 papers (2018–2018)Ezra E.W. Cohen · University of Michigan1 papers (2016–2016)Fabrice André · Institut Gustave Roussy1 papers (2020–2020)